Mitsubishi UFJ Asset Management Co. Ltd. Boosts Holdings in Abbott Laboratories $ABT

Mitsubishi UFJ Asset Management Co. Ltd. increased its position in Abbott Laboratories (NYSE:ABT) by 15.7% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 6,899,393 shares of the healthcare product maker’s stock after purchasing an additional 935,664 shares during the quarter. Abbott Laboratories accounts for 0.7% of Mitsubishi UFJ Asset Management Co. Ltd.’s portfolio, making the stock its 26th largest position. Mitsubishi UFJ Asset Management Co. Ltd.’s holdings in Abbott Laboratories were worth $924,105,000 at the end of the most recent quarter.

A number of other institutional investors have also recently added to or reduced their stakes in ABT. Carr Financial Group Corp increased its position in shares of Abbott Laboratories by 2.0% during the third quarter. Carr Financial Group Corp now owns 3,880 shares of the healthcare product maker’s stock worth $520,000 after acquiring an additional 76 shares during the last quarter. Tortoise Investment Management LLC grew its stake in Abbott Laboratories by 10.7% during the 2nd quarter. Tortoise Investment Management LLC now owns 795 shares of the healthcare product maker’s stock valued at $108,000 after purchasing an additional 77 shares in the last quarter. Gemmer Asset Management LLC increased its holdings in Abbott Laboratories by 2.9% during the 3rd quarter. Gemmer Asset Management LLC now owns 2,750 shares of the healthcare product maker’s stock worth $368,000 after purchasing an additional 78 shares during the last quarter. Bridgewater Advisors Inc. boosted its stake in shares of Abbott Laboratories by 0.6% during the 2nd quarter. Bridgewater Advisors Inc. now owns 12,555 shares of the healthcare product maker’s stock valued at $1,607,000 after buying an additional 79 shares during the last quarter. Finally, Global Financial Private Client LLC grew its position in shares of Abbott Laboratories by 3.3% during the third quarter. Global Financial Private Client LLC now owns 2,469 shares of the healthcare product maker’s stock worth $331,000 after buying an additional 79 shares in the last quarter. Institutional investors and hedge funds own 75.18% of the company’s stock.

Insider Transactions at Abbott Laboratories

In related news, Director Daniel J. Starks acquired 10,000 shares of the stock in a transaction that occurred on Wednesday, February 4th. The shares were acquired at an average price of $108.73 per share, for a total transaction of $1,087,300.00. Following the completion of the purchase, the director directly owned 6,738,817 shares of the company’s stock, valued at $732,711,572.41. The trade was a 0.15% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through the SEC website. 0.46% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

Several research analysts have weighed in on the stock. Weiss Ratings lowered shares of Abbott Laboratories from a “buy (b-)” rating to a “hold (c+)” rating in a report on Monday, January 26th. Leerink Partners decreased their price target on Abbott Laboratories from $136.00 to $119.00 and set a “market perform” rating for the company in a research note on Friday, January 30th. Daiwa Securities Group cut their price objective on Abbott Laboratories from $136.00 to $113.00 and set an “outperform” rating on the stock in a research note on Friday, January 30th. Oppenheimer lowered their price target on Abbott Laboratories from $140.00 to $132.00 and set an “outperform” rating for the company in a report on Friday, January 23rd. Finally, Evercore reduced their price objective on Abbott Laboratories from $144.00 to $138.00 and set an “outperform” rating on the stock in a research note on Friday, January 23rd. Two analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and four have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $137.05.

More Abbott Laboratories News

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: Fool argues Abbott is a steady income/growth pick, citing double‑digit earnings growth and a reliable dividend that make ABT appealing vs. volatile alternatives — supports income-oriented demand. Forget Tilray: This Steady Income Stock Beats Wild Cannabis Swings Every Time
• Positive Sentiment: Industry report: the genetic testing market is forecast to nearly double by 2033, with Abbott listed among leading players — supports long‑term revenue tailwinds for ABT’s diagnostics business. Genetic Testing Market Competitive Landscape Report 2025
• Positive Sentiment: Cancer diagnostics market report projects robust growth to 2033; Abbott appears as a key participant — positive for recurring, higher‑margin diagnostics revenue over time. Cancer Diagnostics Market Competitive Landscape Report 2025
• Positive Sentiment: Personalized medicine market forecasts strong long‑term expansion; inclusion of Abbott underscores exposure to high‑growth therapeutic and diagnostic trends. Personalized Medicine Market Competitive Landscape Report 2025
• Positive Sentiment: Market note: Abbott “ascends while market falls,” reflecting recent positive intraday/short‑term momentum that can attract tactical buyers. Abbott (ABT) Ascends While Market Falls: Some Facts to Note
• Neutral Sentiment: Barchart asks whether Abbott is underperforming the Nasdaq over the last year; while performance lags, analysts remain optimistic — flags valuation/relative‑performance questions but not new fundamental changes. Is Abbott Laboratories Stock Underperforming the Nasdaq?
• Neutral Sentiment: Valuation piece examines whether recent weakness makes ABT attractively priced; useful context for value investors but provides no fresh catalyst. Is Abbott Laboratories (ABT) Pricing Reflect Long Term Value After Recent Share Price Weakness
• Negative Sentiment: Yahoo analysis on evolving Wall Street narrative notes several research houses have cut price targets (some by US$5–29) and flagged execution/earnings translation risk, creating a split analyst view — this analyst skepticism can pressure multiple and cap near‑term upside. How The Evolving Wall Street Narrative Is Reframing Abbott Laboratories (ABT) Valuation Prospects

Abbott Laboratories Stock Performance

ABT stock opened at $114.76 on Thursday. Abbott Laboratories has a 1 year low of $105.27 and a 1 year high of $141.23. The stock has a market capitalization of $199.42 billion, a price-to-earnings ratio of 30.85, a PEG ratio of 1.82 and a beta of 0.75. The company has a debt-to-equity ratio of 0.19, a quick ratio of 1.24 and a current ratio of 1.58. The stock’s fifty day moving average is $117.70 and its two-hundred day moving average is $125.47.

Abbott Laboratories (NYSE:ABT) last issued its quarterly earnings data on Thursday, January 22nd. The healthcare product maker reported $1.50 earnings per share for the quarter, meeting the consensus estimate of $1.50. Abbott Laboratories had a net margin of 14.72% and a return on equity of 17.73%. The firm had revenue of $11.46 billion for the quarter, compared to the consensus estimate of $11.80 billion. During the same period last year, the firm posted $1.34 EPS. Abbott Laboratories’s quarterly revenue was up 4.4% compared to the same quarter last year. Abbott Laboratories has set its Q1 2026 guidance at 1.120-1.180 EPS and its FY 2026 guidance at 5.550-5.800 EPS. On average, research analysts predict that Abbott Laboratories will post 5.14 EPS for the current year.

Abbott Laboratories Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, May 15th. Investors of record on Wednesday, April 15th will be paid a dividend of $0.63 per share. This represents a $2.52 dividend on an annualized basis and a dividend yield of 2.2%. The ex-dividend date is Wednesday, April 15th. Abbott Laboratories’s payout ratio is currently 67.74%.

Abbott Laboratories Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.